Sodium channel protein type 9 subunit alpha (SCN9A) is a 113.5-kb gene comprising 26 exons. It encodes a sodium channel which is composed of 1977 amino acids and is organized into 4 domains, each with 5 hydrophobic segments (S1, S2, S3, S5, S6) and one positively charged segment (S4). Segments S4 are probably the voltage-sensors and are characterized by a series of positively charged amino acids at every third position. The SCNA family of sodium channels (SCN1A-SCN11A) evolved from an archetypal potassium channel by quadruplication, where four potassium subunits must coalesce to form the functional potassium channel.
|Basic Information of SCN9A|
|Protein Name||Sodium channel protein type 9 subunit alpha|
|Aliases||Neuroendocrine sodium channel1 (hNE-Na1 Publication), Peripheral sodium channel 1 (PN1By), Sodium channel protein type IX subunit alpha, Voltage-gated sodium channel subunit alpha Nav1.7|
|Organism||Homo sapiens (Human)|
The SCN9A or NaV1.7 channels are voltage-gated sodium channels expressed in dorsal root ganglia and sympathetic neurons. They mediate cellular excitability and are crucial players in gating pain transmission from the periphery to the central nervous system (CNS). Genetic and functional studies have shown that mutations in SCN9A are the major contributors to pain signaling and pain disorders in humans. Inactivating mutations in SCN9A, which cause loss-of-function of SCN9A channels, result in congenital insensitivity to pain, whereas gain-of-function mutations (single amino-acid substitutions) of SCN9A are linked to 3 pain syndromes: inherited erythromelalgia, paroxysmal extreme pain disorder, and idiopathic small nerve fiber neuropathy (I-SFN).
Fig.1 Location of characterized CIP and IEM-associated mutations in NaV1.7. Schematic representation of NaV1.7 showing the 24 transmembrane (TM) domains contained within four regions (DI-IV). (Emery, 2015)
This article finds complex genotype-phenotype correlations that exist in SCN9A and highlights the C-terminal cytoplasmic region of NaV1.7 as a critical region for channel function, potentially facilitating analgesic drug development studies.
This article suggests that SCN9A NAT as a prime candidate for new therapies based upon augmentation of existing antisense RNAs in the treatment of chronic pain conditions in man.
This article suggests a role of SCN9A in the disease etiology of neuropathic pain.
This article reveals that SCN9A SNPs in basal pain perception may lead to more individualized pain treatment for young women in the future.
This article identifies a de novo missense mutation in the S4-5 linker of the first domain of the Nav1.7 channel in a patient with early-onset paroxysmal pain attacks and erythema involving the hands, feet, and perineal area, suggesting an overlap PE/PEPD phenotype.
Membrane protein studies have advanced significantly over the past few years. Based on our versatile Magic™ membrane protein production platform, we could offer a series of membrane protein preparation services for worldwide customers in reconstitution forms as well as multiple active formats. Aided by our versatile Magic™ anti-membrane protein antibody discovery platform, we also provide customized anti-SCN9A antibody development services.
During the past years, Creative Biolabs has successfully generated many functional membrane proteins for our global customers. We are happy to accelerate the development of our clients’ programs with our one-stop, custom-oriented service. For more detailed information, please feel free to contact us.